ATE317432T1 - Hiv-spezifische oligonukleotide und verfahren zu deren verwendung - Google Patents

Hiv-spezifische oligonukleotide und verfahren zu deren verwendung

Info

Publication number
ATE317432T1
ATE317432T1 AT98939243T AT98939243T ATE317432T1 AT E317432 T1 ATE317432 T1 AT E317432T1 AT 98939243 T AT98939243 T AT 98939243T AT 98939243 T AT98939243 T AT 98939243T AT E317432 T1 ATE317432 T1 AT E317432T1
Authority
AT
Austria
Prior art keywords
hiv
specific oligonucleotides
nucleotides
disclosed
genome
Prior art date
Application number
AT98939243T
Other languages
English (en)
Inventor
Sudhir Agrawal
Original Assignee
Idera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idera Pharmaceuticals Inc filed Critical Idera Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE317432T1 publication Critical patent/ATE317432T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98939243T 1997-08-19 1998-08-05 Hiv-spezifische oligonukleotide und verfahren zu deren verwendung ATE317432T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91482797A 1997-08-19 1997-08-19

Publications (1)

Publication Number Publication Date
ATE317432T1 true ATE317432T1 (de) 2006-02-15

Family

ID=25434822

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98939243T ATE317432T1 (de) 1997-08-19 1998-08-05 Hiv-spezifische oligonukleotide und verfahren zu deren verwendung

Country Status (9)

Country Link
US (2) US20020168340A1 (de)
EP (1) EP1007657B1 (de)
JP (1) JP2001514884A (de)
AT (1) ATE317432T1 (de)
AU (1) AU8771398A (de)
CA (1) CA2300352A1 (de)
DE (1) DE69833438T2 (de)
ES (1) ES2255732T3 (de)
WO (1) WO1999009154A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2255732T3 (es) * 1997-08-19 2006-07-01 Idera Pharmaceuticals, Inc. Oligonucleotidos especificos de vih y procedimientos para su utilizacion.
EP2314693A3 (de) * 1999-08-13 2012-11-28 Idera Pharmaceuticals, Inc. Modulierung der durch CpG-oligonukleotide verursachte Immunstimulierung durch positionsbedingte Veränderung von Nukleosiden
US20090075256A1 (en) * 2000-06-17 2009-03-19 Third Wave Technologies, Inc. Nucleic Acid Accessible Hybridization Site Identification Using Mass Spectrometry
WO2001098537A2 (en) * 2000-06-17 2001-12-27 Third Wave Technologies, Inc. Nucleic acid accessible hybridization sites
US7169365B2 (en) * 2002-03-26 2007-01-30 Evolution Industries, Inc. Automotive exhaust component and method of manufacture
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7345163B2 (en) * 2002-08-28 2008-03-18 Quiatech Ab Process for separating and deprotecting oligonucleotides
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
CN1301263C (zh) * 2002-12-18 2007-02-21 北京昭衍新药研究中心 一组抗hiv感染及防治艾滋病的核苷酸序列及其应用
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
WO2005078094A2 (en) * 2004-02-06 2005-08-25 Dharmacon, Inc. Stabilized rnas as transfection controls and silencing reagents
US20090280567A1 (en) * 2004-02-06 2009-11-12 Dharmacon, Inc. Stabilized sirnas as transfection controls and silencing reagents
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US20060166234A1 (en) * 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
US7935811B2 (en) * 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US8362525B2 (en) * 2005-01-14 2013-01-29 Nantero Inc. Field effect device having a channel of nanofabric and methods of making same
US20060223777A1 (en) * 2005-03-29 2006-10-05 Dharmacon, Inc. Highly functional short hairpin RNA
AU2007299705B2 (en) * 2006-09-22 2012-09-06 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
US7845686B2 (en) * 2007-12-17 2010-12-07 S & B Technical Products, Inc. Restrained pipe joining system for plastic pipe
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5208321A (en) * 1988-06-09 1993-05-04 Institut Pasteur HIV-2 transmembrane glycoprotein homodimer (GP 80)
US5652355A (en) * 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
DK0664833T3 (da) 1992-10-05 1997-04-14 Hybridon Inc Terapeutisk anti-HIV oligonukletid og lægemiddel
US5627277A (en) * 1992-12-16 1997-05-06 Hybridon, Inc. Method for analyzing oligonucleotide analogs
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
WO1995011813A1 (en) 1993-10-26 1995-05-04 Kinetic Limited Vehicle suspension system
US6645943B1 (en) * 1994-10-25 2003-11-11 Hybridon, Inc. Method of down-regulating gene expression
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US6608035B1 (en) * 1994-10-25 2003-08-19 Hybridon, Inc. Method of down-regulating gene expression
US5652356A (en) * 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
AU6553398A (en) 1997-03-12 1998-09-29 Hybridon, Inc. Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides
ES2255732T3 (es) * 1997-08-19 2006-07-01 Idera Pharmaceuticals, Inc. Oligonucleotidos especificos de vih y procedimientos para su utilizacion.

Also Published As

Publication number Publication date
CA2300352A1 (en) 1999-02-25
JP2001514884A (ja) 2001-09-18
AU8771398A (en) 1999-03-08
WO1999009154A2 (en) 1999-02-25
US20030100521A1 (en) 2003-05-29
EP1007657A2 (de) 2000-06-14
DE69833438D1 (de) 2006-04-20
EP1007657B1 (de) 2006-02-08
ES2255732T3 (es) 2006-07-01
US20020168340A1 (en) 2002-11-14
WO1999009154A3 (en) 1999-05-06
DE69833438T2 (de) 2006-10-26
US7173014B2 (en) 2007-02-06

Similar Documents

Publication Publication Date Title
ATE317432T1 (de) Hiv-spezifische oligonukleotide und verfahren zu deren verwendung
FI925103A0 (fi) Antisense-inhibitorer av humant immunbristvirus
DE69333698T2 (de) Pseudo-halbknoten ausbildende rna durch hybridisierung von antisenseoligonnukleotiden an gezielte rna sekundärstrukturen
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
DE69620906D1 (de) Antisense-oligonukleotidmodulation der raf-genexpression
Giovannangeli et al. Efficient Inhibition of Transcription Elongationin vitroby Oligonucleotide Phosphoramidates Targeted to Proviral HIV DNA
NO951307L (no) Terapeutiske anti-HIV oligonukleotider
ATE309345T1 (de) Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
EP0977767A4 (de) Aminooxy-modifizierte oligonukleotide
AU6527094A (en) Modified oligonucleotides having improved anti-influenza activity
ATE318273T1 (de) Zuckermodifizierte oligonukleotide zum erkennen und steuern der genexpression
DE68925278D1 (de) Hemmung von htlv-iii durch exogene oligonukleotide
Volkmann et al. Inhibition of HIV-1 reverse transcription by triple-helix forming oligonucleotides with viral RNA
RU98100921A (ru) Праймеры для обнаружения вич-1
DE69836395D1 (de) Primern zum Nachweis von HIV-1
AR018099A1 (es) Metodo de bloqueo de sintesis de la 17beta-hidroxiesteroide dehidrogenasa del tipo 5 y metodo para interferir su expresion
HU9203452D0 (en) Method for modulation of gene expression
Boiziau et al. Antisense oligonucleotides inhibit in vitro cDNA synthesis by HIV-1 reverse transcriptase
Praseuth et al. Unexpected effect of an anti-human immunodeficiency virus intermolecular triplex-forming oligonucleotide in an in vitro transcription system due to RNase H-induced cleavage of the RNA transcript
Crooke et al. Section Review Biologicals & Immunologicals: Progress in the development and patenting of antisense drug discovery technology
Hélène et al. Sequence-targeted photochemical reactions in single-stranded and double-stranded nucleic acids by oligonucleotide-photosensitizer conjugates
ATE332981T1 (de) Einzelsträngige oligonukleotide, sonden, primer und ein vefahren zur detektion von spirochaeten
EP1043407A3 (de) Sonden für den Nachweis und Characterisierung von HIV-1 Sorten die in chi sequenz gesteuerte Rekombinierung teilnehmen
WO2003097661A3 (en) Antiviral phosphorothioate oligonucleotides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties